SCHEMBL807578

SCHEMBL807578

COC(=O)C1CC(C(C)C)CN(Cc2c(F)cccc2F)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 3/20 0.43
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.38
EED O75530 2/20 0.37
ACHE P22303 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
S1PR1 P21453 1/20 0.37
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CD274 Q9NZQ7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807590 0.92 L3MBTL1 (0.42) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15081966 0.87 ALDH1A1 (0.41) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15084389 0.84 ALDH1A1 (0.46) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15081968 0.82 TACR1 (0.42) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15081969 0.78 EED (0.39) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL807178 0.77 EED (0.43) ALDH1A1KDM4ETSHRSMN1; SMN2POLB
SCHEMBL15084376 0.77 L3MBTL1 (0.44) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL2728930 0.76 L3MBTL1 (0.44) ALDH1A1KDM4ETSHRTDP1L3MBTL1
SCHEMBL15081999 0.73 MAPK1 (0.44) SMN1; SMN2EEDMAPK1
SCHEMBL807398 0.72 CYP2A13 (0.48) ALDH1A1KDM4ETSHRTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 ALDH1A1 781/4885KDM4E 3317/4885TSHR 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.